Opal Wealth Advisors LLC and
Atria Investments Inc have bought shares in IDEXX Laboratories Inc, while
Janus Henderson Group PLC and insiders have offloaded the stock, signaling a possible bearish trend. The company's Q2 earnings, although surpassing certain estimates with revenue of $1,004m, missed estimates by $0.44 EPS.
IDEXX Laboratories cut full-year outlook after these earnings results which led to a decrease in share price. Despite the lower outlook,
BTIG initiated coverage with a buy recommendation, and market watchers remain optimistic about the long-term growth of the bio-tech company. The company is expanding the test menu for its
Catalyst Platform for diagnosing pancreatitis in pets and has announced a revolutionary, slide-free cellular analyzer,
IDEXX inVue Dx™, simplifying in-clinic workflows. The company also launched
Vello™, software that enhances pet owner engagement, after acquiring
ezyVet.
Idexx Laboratories IDXX News Analytics from Mon, 25 Jun 2018 12:11:19 GMT to Sun, 11 Aug 2024 13:53:36 GMT -
Rating -5
- Innovation 4
- Information 7
- Rumor -2
